Charles River Laboratories Announces Launch of Triple-Immunodeficient Mouse Model for Oncology Research
April 03 2017 - 8:00AM
Business Wire
Charles River Laboratories International, Inc. (NYSE: CRL), a
leading early-stage contract research organization (CRO), announced
the North American launch of its triple-immunodeficient mouse
model, known as the NCG model. The NCG model is the first
CRISPR-generated immunodeficient model offered by Charles River,
and was developed by altering the Prkdc and Il2rg genes.
“The launch of Charles River’s NCG model provides a significant
opportunity to assist our clients in the development of
life-saving, translational therapies,” said Dr. Iva Morse,
Corporate Vice President, Chief Scientific Officer, Global Research
Models and Services. “The availability of this model, combined with
our scientific expertise, will allow us to work with clients to
advance the application of humanized studies in oncology, among
other therapeutic areas.”
The NCG model was co-developed by the Nanjing Biomedical
Research Institute of Nanjing University and Nanjing Galaxy
Biopharma, and transferred to Charles River in 2016. The NCG model
is similar to other triple-immunodeficient models in that it is
capable of hosting xenograft cells, tissue, and human immune system
components, enabling researchers to further study tumor biology and
immuno-oncology.
This model complements Charles River’s extensive portfolio of
oncology products and services, including studies in human
xenograft, syngeneic, and humanized immunotherapy research models,
flow cytometry, and IVIS® imaging services. In November 2015,
the Company acquired Oncotest GmbH, a Freiburg, Germany-based
organization with a specialization in patient-derived xenograft
(PDX) models, and in November 2016, partnered with OcellO to
provide translational in vitro PDX and in vivo PDX oncology drug
discovery services.
Charles River is introducing the NCG model to its North American
customer base at the 2017 AACR Annual Meeting, which highlights the
best cancer science and medicine from institutions all over the
world. A full schedule of Charles River’s activities during the
2017 AACR Annual Meeting is available on their website, and
reprints of each poster are available in Charles River’s booth
(#1421) during the conference. Additionally, experts are available
to discuss the NCG model, as well as their capabilities and
expertise in oncology research. Throughout the conference, Charles
River will be providing live updates on the Eureka Blog,
including reviews of scientific sessions and input on the research
being presented.
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their
research and drug development efforts. Our dedicated employees are
focused on providing clients with exactly what they need to improve
and expedite the discovery, early-stage development and safe
manufacture of new therapies for the patients who need them. To
learn more about our unique portfolio and breadth of services,
visit www.criver.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170403005053/en/
Charles River Laboratories International, Inc.Amy Cianciaruso,
781-222-6168Corporate Vice President, Public
Relationsamy.cianciaruso@crl.comorSusan E. Hardy,
781-222-6190Corporate Vice President, Investor
Relationssusan.hardy@crl.com
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Apr 2023 to Apr 2024